Floor 7, Building 12, No.2 Kechuang Sixth Street, E-town Beijing, 102600 ChinaBeijing Life Biosciences Co., Ltd. ("LifeBio") was established in 2021 with the mission of building a world-class platform for model animals and translational research services for innovative drugs and medical devices. The company is distinguished by its focus on large and medium-sized model animals, particularly non-human primates, and scarce specialized disease models, guided by the core value of "accelerating translational outcomes and expediting the market launch of pharmaceuticals and devices." LifeBio offers nearly 200 specialized disease models and experimental services across key therapeutic areas including central nervous system and brain science, psychiatry and neuromodulation, chronic metabolic diseases, oncology, and ophthalmology. Its offerings cover spontaneous disease models, induced models, genetically engineered models, and surgical models. The company places particular strategic emphasis on the unique value of large and medium-sized animal models in accelerating preclinical translational validation for cutting-edge drugs and innovative devices. Currently, LifeBio has established a nationally distributed, high-standard industrial chain for large and medium-sized laboratory animal resources, with multiple experimental facilities and SPF-grade barrier housing facilities across the Beijing–Tianjin–Hebei region, the Yangtze River Delta, and the Greater Bay Area. The company holds comprehensive qualifications including Laboratory Animal Production Licenses and Use Licenses.

Room 1502, Building 3B, Hengtaiyu Building, Tonggong Road, Fenghuang Street, Guangming District Shenzhen, Guangdong, 518000 ChinaBeijing Life Biosciences Co., Ltd. ("LifeBio") was established in 2021 with the mission of building a world-class platform for model animals and translational research services for innovative drugs and medical devices. The company is distinguished by its focus on large and medium-sized model animals, particularly non-human primates, and scarce specialized disease models, guided by the core value of "accelerating translational outcomes and expediting the market launch of pharmaceuticals and devices." LifeBio offers nearly 200 specialized disease models and experimental services across key therapeutic areas including central nervous system and brain science, psychiatry and neuromodulation, chronic metabolic diseases, oncology, and ophthalmology. Its offerings cover spontaneous disease models, induced models, genetically engineered models, and surgical models. The company places particular strategic emphasis on the unique value of large and medium-sized animal models in accelerating preclinical translational validation for cutting-edge drugs and innovative devices. Currently, LifeBio has established a nationally distributed, high-standard industrial chain for large and medium-sized laboratory animal resources, with multiple experimental facilities and SPF-grade barrier housing facilities across the Beijing–Tianjin–Hebei region, the Yangtze River Delta, and the Greater Bay Area. The company holds comprehensive qualifications including Laboratory Animal Production Licenses and Use Licenses.